Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.
Br J Cancer
; 119(2): 193-199, 2018 07.
Article
en En
| MEDLINE
| ID: mdl-29973670
ABSTRACT
BACKGROUND:
Prescribing anti-programmed death-1 (PD-1) immunotherapy for advanced melanoma is currently not restricted by any biomarker assessment. Determination of programmed death-ligand-1 (PD-L1)-expression status is technically challenging and is not mandatory, because negative tumours also achieve therapeutic responses. However, reproducible biomarkers predictive of a response to anti-PD-1 therapy could contribute to improving therapeutic decision-making.METHODS:
This retrospective study on 70 metastatic melanoma patients was undertaken to evaluate the relationships between clinical, histological, immunohistochemical and/or molecular criteria, and the 6-month objective response rate.RESULTS:
Better objective response rates were associated with metachronous metastases (P = 0.04), PD-L1 tumour- and/or immune-cell status (P = 0.01), CD163+ histiocytes at advancing edges (P = 0.009) of primary melanomas and NRAS mutation (P = 0.019). Moreover, CD163+ histiocytes at advancing edges (P = 0.04) were associated with longer progression-free survival (PFS), and metachronous metastases with longer overall survival (P = 0.02) and PFS (P = 0.049).CONCLUSIONS:
Combining these reproducible biomarkers could help improve therapeutic decision-making for patients with progressive disease.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Antígenos de Diferenciación Mielomonocítica
/
Antígenos CD
/
Neoplasias Primarias Secundarias
/
Receptores de Superficie Celular
/
Antígeno B7-H1
/
Receptor de Muerte Celular Programada 1
/
Melanoma
Tipo de estudio:
Observational_studies
/
Prognostic_studies
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Br J Cancer
Año:
2018
Tipo del documento:
Article
País de afiliación:
Francia